The Trump administration has launched a new effort to accelerate research into ibogaine, a powerful psychedelic compound derived from the African iboga plant. President Donald Trump signed an executive order aimed at reducing regulatory barriers and expanding clinical studies on psychedelic therapies for serious mental illnesses and addiction. (The White House)

Key points:

• Ibogaine is a hallucinogenic substance traditionally derived from the root of the Tabernanthe iboga shrub, native to Central Africa. It remains a Schedule I drug in the United States, meaning it is not approved for medical use. (Wikipedia)
• Researchers are studying whether ibogaine could help treat:
  • Opioid and other substance-use disorders
  • Depression
  • Post-traumatic stress disorder (PTSD)
  • Traumatic brain injury symptoms in veterans (Houston Chronicle)
• The executive order directs federal agencies to speed up research, increase access to clinical trials, and work with the Department of Veterans Affairs. It also allocates funding to support state-level psychedelic research programs. (The White House)
• Safety concerns remain significant. Ibogaine has been linked to serious side effects, including heart rhythm abnormalities, seizures, psychosis, nausea, and, in rare cases, death. Experts emphasize that its effectiveness and long-term safety have not yet been conclusively proven. (Houston Chronicle)
• States such as Texas have already invested millions of dollars into ibogaine research, hoping to develop FDA-approved treatments in the future. (Houston Chronicle)